To facilitate development of cancer stem cell (CSC)-targeting therapies, we analyzed publicly available breast cancer data sets to identify genes coexpressed with sex-determining region Y (SRY)-related high-mobility group (HMG) box-containing factor 10 (SOX10), a neural crest marker, and prominin 1 (PROM1)/CD133, a common CSC marker. The conserved SOX10/PROM1 gene signature that we characterized supports the existence in basal breast cancers of SOX10-positive (SOX10 D )/CD133 D cells with neural stem-like features exposing clinically relevant CSC markers and signaling networks. Background: We previously characterized in salivary adenoid cystic carcinoma (ACC) a novel population of cancer stem cells (CSCs) marked by coexpression of 2 stemness genes, sex-determining region Y (SRY)-related HMG box-containing factor 10 (SOX10) and CD133. We also reported that in ACC and basal-like breast carcinoma (BBC), a triple-negative breast cancer subtype, expression of SOX10 similarly demarcates a highly conserved gene signature enriched with neural stem cell genes. On the basis of these findings, we hypothesized that BBC might be likewise driven by SOX10-
Introduction
Cancer stem cells (CSCs) are attractive therapeutic targets because of their abilities to maintain tumor growth, invade, metastasize, withstand cytotoxic therapies, and recur. 1 However, isolation of CSCs from tumor specimens is challenging, especially when information on clinically relevant cell surface markers is lacking. Most published CSC studies relies on in vitro studies, but significance of CSC markers derived from cell lines is questionable, especially when their expression in clinical specimens is not confirmed. [2] [3] [4] [5] [6] We believe that molecular profiling of clinical specimens could help the pursuit of clinically relevant CSCs. If CSCs with similar properties are shared across tumor specimens, such cells can be tracked according to gene expression patterns conserved between patients. It can be also argued that stemness markers related to cell of origin can be shared by cancers with similar histogenesis and exposed via gene expression profiling. A remarkable example of such a marker is sex-determining region Y (SRY)-related highmobility group (HMG) box-containing factor (SOX) 10 (SOX10), which plays pivotal roles in gliogenesis, melanogenesis, differentiation of myoepithelial cells and other lineages that originate from neural crest, and maintenance of adult neural stem cells (NSCs) that reside in the subventricular central nervous system (CNS) zone. [7] [8] [9] [10] [11] [12] [13] [14] [15] Recent studies that characterized SOX10 as a melanoma driver, 16 and a key breast stem cell regulator 17 raised the important question about SOX10 relevance to stem cell maintenance in a certain group of cancers. Our previously performed expression analysis of clinical specimens of adenoid cystic carcinoma (ACC), a highly lethal neuroinvasive cancer of salivary glands, identified in 94% of ACC transcripts of SOX10, neurogenic locus notch homolog protein 1 (NOTCH1), fatty acid binding protein 7 (FABP7), and other NSC genes 18 whose coexpression was remarkably consistent from patient to patient. The most plausible explanation for this phenomenon was the existence in most ACC of a previously uncharacterized population of CSCs with NSC properties. Indeed, our recent experiments performed on cultured ACC cells and patient-derived xenograft (PDX) models showed that SOX10 marks a previously unrecognized population of CD133-positive (CD133 þ ) stem cells that express stemness genes and form tumors with ACC histology when injected into nude mice. 19 Overall, these experiments validated SOX10 as a valuable cell lineage marker and key ACC-CSC regulator, suggesting that identification of genes associated with SOX10 activation might provide important insights into molecular features of previously uncharacterized CSCs in SOX10 þ cancers.
Interestingly, we and others previously showed that SOX10 expression is also diagnostic for basal-like breast carcinoma (BBC), a breast cancer subtype distinguished with myoepithelial-like gene expression profile and myoepithelial differentiation akin to ACC. 8, 13, 14, 17 BBC as a triple-negative breast cancer (TNBC) subtype was described 15 years ago on the basis of a characteristic gene expression signature found in approximately 15% of breast cancer specimens. [20] [21] [22] This finding was the first molecular insight into BBC that urgently requires targeted therapies because of the absence of estrogen, progesterone, and erb-b2 receptor tyrosine kinase 2 (ERBB2) receptors, shows poor prognosis, and affects young women. 23 On the basis of the observed similarities between ACC and BBC, we hypothesized that SOX10 promotes in both cancers CD133 þ cells with stem cell properties that could be tracked in clinical tumor specimens via genes that are coexpressed with CD133 and SOX10.
Tracking conserved elements of gene expression patterns across multiple specimens and data sets requires a reliable noise-resistant and straightforward algorithm for meta-analysis. In this study, using Multi Experiment Matrix (MEM; http://biit.cs.ut.ee/mem) meta-analysis that merges information from different Affymetrix (Thermo Fisher Scientific Inc., Maltham, MA) data sets into a single global ordering and ranks genes according to their coexpression, 24 we confirm that CD133 and SOX10 coexpression in breast cancers is highly statistically significant, intrinsic to BBC specimens, and clinically and biologically relevant. This observation supports our hypothesis on the existence in BBC of SOX10 þ / CD133 þ cells with neural stem properties and provides a blueprint for identification of true CSCs and their targeting.
Materials and Methods
Meta-analysis of publicly available breast cancer data sets was performed using MEM software and data sets produced on Affymetrix U133 plus 2.0 platform (Thermo Fisher Scientific Inc). MEM ranks Affymetrix probes/genes (Thermo Fisher Scientific Inc) according to statistical score assigned on the basis of coexpression of these probes with the gene of interest across multiple data sets. To improve biological and clinical aspects of the analysis, MEM allows access to individual data sets, performs stratification of output data, and builds heat maps to identify clinical groups with differential gene expression. 24, 25 Cross-validation of meta-data was done with cBioPortal software on a TCGA Breast Invasive Carcinoma data set at http://www. cbioportal.org/study?id¼brca_tcga#summary. This data set was produced on 1105 clinical specimens collected from 1098 patients and combines mutational analysis with DNA copy number variation, gene expression array, and reverse phase protein array (RPPA) data.
Breast cancer PDX models were profiled using an E-GEOD-46106 data set and software available at BioGPS (www.biogps.org). This data set was produced using the U133 Plus 2.0 Affymetrix platform (Thermo Fisher Scientific Inc) on xenografts established from 25 breast cancer patients.
Analysis of discriminators for breast cancer groups was done via http://www.ncbi.nlm.nih.gov/geo/geo2r, a Web tool available via Gene Expression Omnibus for comparative statistical analysis between 2 or more groups for identification of differentially expressed genes.
Gene ontology analysis was done via http://software. broadinstitute.org/gsea, a computational method that determines whether a priori defined sets of genes show statistically significant, concordant differences between 2 biological states (eg, phenotypes).
Gene expression analysis of human primary cells was performed using a Primary Cell Atlas data set (http://biogps.org/dataset/BDS_ 00013) and software available at BioGPS. This data set combines 745 samples from > 100 studies performed on human primary cells. Although VGLL1 relation to stem cell maintenance in BBC remains unclear, its paralog VGLL4 promotes survival of human embryonic stem cells 34 and regulates Hippo-YAP (Yes-associated protein 1) signaling in postnatal cardiomyocytes. 35 Other previously published BBC markers that we found in the PROM1 signature were transcription factors E74-like ETS transcription factor 5 (ELF5), B-cell lymphoma/leukemia 11A (BCL11A), and SOX9, all of them linked to promotion of progenitor/stem cells in breast cancer and normal breast, [36] [37] [38] [39] and cadherin 3 (CDH3)/P-cadherin, a breast basal stem cell marker. 40 Thus, our analysis of the PROM1/ CD133 MEM signature was consistent with the existence in BBC, but not other breast cancer types, SOX10 þ /CD133 þ cells that are molecularly similar to ACC-CSCs and express stem cell genes previously linked to ACC as well as BBC.
Results

Expression
CD133 Expression in Breast Cancer Is BBC-Selective
Our hypothesis that the CD133/PROM1 gene signature is BBCselective was then validated on 1 of the 23 data sets used in the MEM analysis, E-GEOD-21653, which stratified clinical specimens into 5 major groups: ERBB2, BBC, luminal A, luminal B, and normal-like subtypes (total n ¼ 266). The heat map built for this study at http://biit.cs.ut.ee/mem revealed that PROM1 is strongly and consistently expressed in most BBC (approximately 80%), in a fraction of ERBB2 þ tumors, and in the normal-like tumor group, but to a much lesser extent in the luminal subtypes ( Figure 2 ). In line with this finding, CD133/PROM1 was among the top 250 discriminators of the BBC subtype in our analysis of distribution of gene expression across 5 breast cancer groups (http://www.ncbi. nlm.nih.gov/geo/geo2r, adjusted P ¼ 7.7E-29). We also observed expression of PROM1 in normal-like breast specimens included in E-GEOD-21653 ( Figure 2 ) as well as in normal breast specimens represented in other data sets that we analyzed (data not shown), which was in line with previously published reports on PROM1 expression in normal breast. 41 Interestingly however, some PROM1
signature genes, such as ROPN1, ROPN1B, myelin protein zero-like 2 (MPZL2), grainyhead-like transcription factor 1 (GRHL1), lipocalin 2 (LCN2), melanoma-derived growth regulatory protein (MIA), Kruppel-like factor 5 (KLF5), forkhead box C1 (FOXC1), p53 apoptosis effector related to PMP-22 (PERP), and VGLL1 (shown with arrows in Figure 2 ), appeared to be more selective to cancerous tissue that PROM1. Overall, our analysis strongly supports a major role for SOX10 þ /CD133 þ cells in BBC providing a set of novel molecular markers for these prospective CSCs and a new insight into signaling pathways involved in their maintenance.
Cross-Validation of the PROM1 Gene Signature
Because MEM rank aggregation analysis has not been previously used for CSC tracking, we validated our PROM1 gene signature on a large breast cancer data set (Breast Invasive Carcinoma, TCGA Provisional, n ¼ 1093, RNA-Seq and RPPA data available from http://www.cbioportal.org). In this data set, statistically significant associations found between SOX10, PROM1, and core SOX10 signature genes supported the results of our MEM analysis (Table 1) . Using standard Pearson and Spearman score calculation, a list of genes positively and negatively correlating with PROM1 in the TCGA data set was generated (r cutoff, 0.5; see Supplemental Table 1 in the online version; n ¼ 197) and compared with the MEM-generated PROM1 gene signature shown in Figure 1 . Remarkably, 80% of these PROM1 signature genes (33 of 41) were reproduced in this validation study as positively correlating with PROM1 (see Supplemental Table 1 in the online version, gray rows). However, estrogen receptor (ESR1; r ¼ À0.62), as well as forkhead box A1 (FOXA1) (r ¼ À0.55) and GATA-binding protein 3 (GATA3) (r ¼ À0.56), 2 transcription master regulators and molecular markers of sex hormone receptor-positive breast cancers, 42 were at the very bottom of the list of genes with the highest negative correlation with PROM1. We then used RPPA data available with the TCGA data set and showed that PROM1-expressing specimens were mostly ESR1, progesterone receptor (PGR), and ERBB2/HER2
À (e-10 < P < e-27) and overexpressed NOTCH1 (P approximately e-7), CDH3 (P approximately e-3), and previously published BBC markers (see Supplemental Table 2 in the online version). Overall, cross-validation of our MEM meta-analysis on an independent cohort at RNA as well as protein levels strengthened clinical relevance of our findings and produced new information of their molecular identity.
Identification of TRIM2, TRIM29, MPZL2, Potassium Calcium-Activated Channel Subfamily N Member 4 (KCNN4), and V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1)/B7 Homolog 4 (B7H4) Within the PROM1 Gene Signature Suggests Strategies for CSC Eradication
Within the PROM1 signature, we found genes that, to our knowledge, have not been previously associated with BBC/TNBC ( Figure 1, red font) . Two of these genes were represented by TRIM proteins implicated in neurodegenerative disorders, axonopathies, and ataxia. [43] [44] [45] The TRIM2 function in cancers has been associated with its E3 ubiquitin ligase activity toward BIM/BCL2L11 SOX10D/CD133D Gene Signature in Basal Breast Cancers activities of TRIM29 appear to be mediated via multiple mechanisms because its overexpression in cancers was linked with suppression of p53, PTEN (phosphatase and tensin homolog), and promotion of radioresistance and other stem cell properties. [48] [49] [50] [51] Other potentially useful therapeutic targets within the PROM1 signature were MPZL2/EVA1, which has been recently linked to maintenance of glioblastoma stem cells through activation of the noncanonical nuclear factor kB pathway, 52 and potassium calciumactivated channel subfamily N member 4 (KCNN4) that encodes potassium channel KCa3.1 involved in regulation of motility in glioblastoma stem cells. 53 One of the most intriguing genes that we associated with PROM1 expression was V-set domain containing T cell activation inhibitor 1 (VTCN1), which encodes B7 homolog 4 (B7H4), a checkpoint receptor in immune tolerance regulation. 54 Interestingly, expression of B7-H4 has been previously shown in CSCs in neuroectodermal tumors and linked to stimulation of CSCs in renal cell carcinoma, where it was essential for tumor growth, chemoresistance, and immune evasion. 55, 56 Supporting their clinical relevance, all of these 5 genes passed cross-validation on the TCGA data set (see Supplemental Table 1 in the online version). Thus, tracking CSCs in clinical specimens according to their molecular markers might provide valuable information on genes and signaling pathways intrinsically linked to poor prognosis, which might facilitate development of CSC-targeting therapies for BBC and other cancers.
Expression of PROM1 in BBC Is Paralleled by Activation of Neural Stem Genes
Our previous studies associated SOX10 and PROM1/CD133 expression in ACC with expression of NSC genes and markers. 14, 18, 19 To find out if this is also true for BBC, we performed enrichment analysis of genes listed in Supplemental Table 1 in the online version. Our Gene Set Enrichment Analysis (GSEA) analysis with software available from http://software.broadinstitute.org/gsea/index.jsp revealed that the list of 149 genes coexpressed with PROM1 show highly statistically significant overlaps with CNS Development and Neurogenesis GO sets (see Supplemental Table 3 in the online version). Smoothened (SMO), inhibitor of DNA binding 4 (ID4), FABP7, nuclear factor I B (NFIB), Frizzled 9 (FZD9), C-X3-C motif chemokine ligand 1 (CX3CL1), and LIM domain only 4 (LMO4) that have been previously characterized as key signaling factors involved in NSC regulation were the most interesting genes in these overlaps with therapeutic potential. 
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Figure 2 Heat Map of the E-GEOD-21653 Data Set Produced by Multi Experiment Matrix (http://biit.cs.ut.ee/mem) on Clinical Specimens Sorted Into 5 Breast Cancer Subtypes Illustrates Basal-Like Breast Carcinoma (BBC)-Selective Expression of Top 44 Genes
SOX10D/CD133D Gene Signature in Basal Breast Cancers
Schwann Cell Markers Reveal Similarities Between BBC and Neural Progenitors SRY-related HMG box-containing factor 10 has been previously described as a highly selective marker of Schwann cells. 8, 14 This finding was in line with the key SOX10 role in neural crest development and its differentiation into glial cells and melanocytes. 64 To obtain more information on the potential link between SOX10/PROM1-expressing BBC cells and Schwann cells, we inspected distribution of ROPN1, ROPN1B, MIA, GPM6B, and other genes coexpressed in BBC with either PROM1 or SOX10 across normal human cell lineages using the Primary Cell Atlas data set (http://biogps.org/dataset/BDS_00013). Remarkably, in addition to SOX10 and 4 genes already mentioned, this analysis identified 6 more genes as selectively expressed in Schwann cells and BBC (see Figure 3 and Supplemental Figure 1 in the online version). Of note, MIA, S100 calcium binding protein B (S100B), FABP7, and SHC adaptor protein 4 (SHC4)/RaLP have been previously linked to melanoma [65] [66] [67] [68] and glioma. [69] [70] [71] Overall, we identified 10 basic cell lineage markers shared between ACC, BBC, melanoma, and Schwann cells that strongly supported our hypothesis on the origin of these 3 cancers from Schwann cell precursors ( Figure 3 ). On the basis of these associations, it is reasonable to propose that all of these novel genes/markers, along with SOX10, are CSC-intrinsic factors that play important roles in aggressive cancer behavior and might be used for tracking, isolation, and selective elimination of CSCs as well as for diagnostics, and prognostication of SOX10-positive cancers.
The PROM1/SOX10 Gene Signature Is Partially Maintained in PDX Models of BBC Patient-derived xenografts are becoming common tools in preclinical studies because they maintain tumor heterogeneity, support CSCs, and faithfully mimic tumor response to therapy. 72 To determine if PDX models of BBC can be used for tracking and isolation of SOX10/PROM1-expressing cells, we asked if a publicly available TNBC PDX data set, E-GEOD-47079 (n ¼ 7), maintains expression of genes shown in Figure 1 . This comparison identified in the TNBC data set 56% (23 of 41) of the clinical PROM1 gene signature as close PROM1 correlates (r > 0.65), suggesting that expression of at least half of the PROM1 signature genes is maintained in PDX models (data not shown). Overall, this analysis supported these models as adequate tools for CSC isolation, but also underlined differences in gene expression, which are most likely caused by model limitations, such as murine tissue environment and lack of interaction with the immune system.
Discussion
Cancer stem cells have taken center stage in clinical research because they are considered the root of aggressive tumor behavior and resistance to cytotoxic therapies. However, identification of true CSCs is challenging because CD24, CD44, CD133, and other cell surface markers used for their detection are not cell lineage-or cancer-specific. Thus, inclusion of more definitive markers for reliable and clinically relevant CSC identification is required. 4, 5 Molecular profiling separated clinical breast cancer specimens into 4 major types: luminal, ERBB2-positive, basal-like (BBC), and normal breast. 73 BBC, which comprises approximately 15% to 20% of all breast cancers, is a molecularly and clinically distinct cancer type distinguished with a myoepithelial cell-like expression profile, poor prognosis, and resistance to cytotoxic and hormone receptortargeting therapies. 74 We recently showed that SOX10, a master regulator of NSCs and highly specific marker of Schwann cells and melanocytes, is overexpressed in clinical ACC and BBC specimens This novel SOX10 þ /CD133 þ CSC population, which we named ACC-CSCs, possessed stem cell properties, such as the ability to form spheroids in culture and initiate tumors with ACC histology in nude mice. 19 We then asked if tracking SOX10 and CD133 expression in clinical breast cancer specimens might similarly provide information on CSCs in BBC. In this study, using publicly available clinical data, we were able to track genes coexpressed with PROM1/CD133 and SOX10 across different breast cancer specimens and data sets. Moreover, we identified on the basis of this straightforward approach a conserved gene signature highly enriched with novel and previously reported stem cell markers. Overall, gene coexpression data strongly suggested the existence in BBC of a previously unknown population of CSCs with molecular traits similar to NSCs and cancers of neural crest origin. The validity of our conclusion is strengthened by: (1) successful application of a similar approach to tracking and isolation of CSCs from ACC; (2) cross-validation of breast cancer MEM data on an independent data set using a different platform and calculation algorithm; (3) overlap found between our data and previously published BBC stem cell markers; and (4) Figure 1 (our unpublished data). Thus, experiments with MX-1, one of the oldest cancer cell line/xenograft models which is available from the National Cancer Institute (NCI)-Frederick (https:// frederick.cancer.gov/services/tumorcatalog.aspx), might provide an important insight into molecular signaling of SOX10 þ /CD133 þ cells related to poor prognosis and help with designing CSCtargeted therapies. In summary, our study provides a blueprint for BBC studies focused on CSC isolation, modeling, and targeting as well as for validation of already available and newly derived cell lines and PDX as adequate tools for CSC research. The results of our analysis are consistent with the existence in BBC of SOX10
þ cells with NSC properties and a major role proposed for SOX10 in breast stem cell maintenance. 17 Tracking CSCs in BBC using novel markers that we identified offers new research tools and approaches to improve BBC diagnostics, prognostication, and treatment.
Conclusion
Our study suggests that most clinical BBC specimens contain a population of SOX10 þ /CD133 þ CSCs that coordinately express genes and markers characteristic for NSCs. Highly conserved gene expression patterns associated with SOX10 and CD133/PROM1 expression suggest that these CSCs can be tracked in clinical tumor specimens and PDX models via a large set of coordinately expressed NSC markers. Overall, the results of our study provide a new approach for identification and isolation of true CSCs for basic research as well as for diagnostics, prognostication, and preclinical studies.
Clinical Practice Points
Whereas CSC eradication might be an effective solution for treating cytotoxic therapy-resistant cancers, tracking CSCs in clinical specimens and their isolation from tumor tissue and PDXs is impossible without reliable CSC markers. Our approach to CSC identification in clinical specimens is on the basis of analysis of massive gene expression data with the goal to track potential CSCs according to their conserved gene signatures.
We recently showed that SOX10, a marker of neural crest stem cells and their derivatives, is overexpressed as a part of a conserved gene signature in 2 histologically similar cancers resistant to radio-and chemotherapies, salivary ACC and BBC. Consequently, we showed that SOX10 is a reliable and specific CSC marker in ACC because it marks a novel population of tumor-initiating cells with the SOX10 þ /CD133 þ phenotype.
In this study, we tested our hypothesis that coexpression of SOX10 and PROM1/CD133 might help to identify a similar population of CSCs in BBC. Our results produced on clinical breast cancer gene expression data sets strongly support our hypothesis that BBC, similar to ACC and other SOX10-expressing cancers, is driven by a population of SOX10 þ /CD133 þ cells with neural stem properties that have not been previously recognized in breast cancer. Results of our study suggest that SOX10 þ /CD133 þ cells can be tracked via a large group of coordinately expressed markers in clinical tumor specimens and PDX models validating PDX models as adequate tools for CSC research and preclinical studies aimed at CSC eradication.
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